8-K: IO Biotech Faces Nasdaq Delisting Warning

IO Biotech, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, initiating a 180-day compliance period.

Summary

• IO Biotech, Inc. received a notice from The Nasdaq Stock Market LLC on December 17, 2025, indicating non-compliance with the minimum bid price requirement.
• The company's common stock closing bid price had fallen below $1.00 per share for 30 consecutive trading days, violating Nasdaq Listing Rule 5450(a)(1).
• The notice does not immediately affect the listing of the company's common stock, which will continue to trade on the Nasdaq Global Select Market.
• IO Biotech has been granted an initial compliance period of 180 calendar days, until June 16, 2026, to regain compliance.
• To regain compliance, the closing bid price of the common stock must meet or exceed $1.00 per share for a minimum of 10 consecutive trading days.
• If compliance is not regained by June 16, 2026, the company may be eligible for an additional 180-day compliance period if it applies to transfer its listing to the Nasdaq Capital Market, provided it meets other listing standards and Nasdaq approves.

Sentiment

Score: 3

Explanation: The company received a notice of non-compliance with Nasdaq's minimum bid price rule, indicating significant stock price underperformance and potential delisting risk, though a compliance period is granted.

Negatives

• Received a notice of non-compliance with Nasdaq's minimum bid price requirement.
• The company's stock price has traded below $1.00 for 30 consecutive trading days.
• Risk of delisting from the Nasdaq Global Select Market if compliance is not regained.

Risks

• There is no assurance that the company will be able to regain compliance with the minimum bid price requirement.
• The company may not be able to meet other applicable Nasdaq listing rules.
• Potential delisting of the company's common stock from Nasdaq.
• If delisted, the company may not be eligible for an additional compliance period or transfer to the Nasdaq Capital Market.

Future Outlook

The company faces uncertainty regarding its ability to regain compliance with Nasdaq's minimum bid price requirement. While a 180-day compliance period is granted, there is no assurance that the stock price will recover sufficiently to meet the $1.00 threshold for 10 consecutive trading days. Potential options include seeking an additional compliance period by transferring to the Nasdaq Capital Market, which is also subject to eligibility and Nasdaq's determination.

Management Comments

• IO Biotech, Inc. acknowledges receipt of the notice from Nasdaq regarding non-compliance with the minimum bid price requirement.

Industry Context

Biotechnology companies, particularly those in clinical development stages like IO Biotech, often experience significant stock price volatility due to research and development milestones, clinical trial results, and funding needs. Falling below Nasdaq's minimum bid price can be a common challenge for smaller or earlier-stage biotech firms, reflecting market skepticism or a lack of significant positive catalysts.

Stakeholder Impact

• Shareholders face the risk of potential delisting, which could lead to reduced liquidity, decreased visibility, and a potential decline in share value.
• The company's ability to attract future investment or maintain institutional interest may be negatively impacted by the delisting notice.

Next Steps

• Regain compliance with Nasdaq's minimum bid price requirement by June 16, 2026, by having the common stock's closing bid price meet or exceed $1.00 for at least 10 consecutive trading days.
• If compliance is not regained, potentially apply to transfer the listing of common stock to the Nasdaq Capital Market for an additional compliance period, subject to meeting other listing standards and Nasdaq's approval.

Key Dates

Recommendation

The company's failure to meet Nasdaq's minimum bid price requirement signals significant underlying issues and poses a substantial delisting risk. While a compliance period is granted, the uncertainty and potential for reduced liquidity on a lower market tier or outright delisting make the stock a high-risk investment. Seasoned investors would likely consider selling to avoid further potential losses or reduced market access.

Keywords

IO Biotech, IOBT, Nasdaq, Delisting, Minimum Bid Price, Compliance, Biotech, SEC Filing, 8-K